Abstract #2208

Do gadolinium-based contrast agents alter 23Na T1 relaxivity in glioma?

Frank Riemer¹, Mary A McLean², Fulvio Zaccagna¹, James T Grist¹, Rolf F Schulte³, Joshua Kaggie¹, Colin Watts⁴, Stephen J Price⁴, Martin J Graves¹, and Ferdia A Gallagher¹

¹Department of Radiology, University of Cambridge, Cambridge, United Kingdom, ²Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom, ³GE Global Research, Munich, Germany, ⁴Neurosurgery Division, Dept. of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom

Incomplete fluid suppression on fluid-attenuated inversion-recovery ²³Na-MRI (IR-²³Na-MRI) was observed in three patients undergoing IR-²³Na-MRI after gadolinium contrast injection, as part of a brain tumour imaging study. To evaluate this, ²³Na-MRI T₁ maps were acquired before and after injection of a gadolinium-based contrast agent on a grade IV glioma (GBM) patient, which showed a statistically significant change of ²³Na-MRI T₁ within the peritumoral oedema (p=0.0095). Gadolinium contrast-enhanced ²³Na-MRI could potentially add further applications for sodium imaging and probe tumour tissue structure in new ways to investigate proliferation and treatment response.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.